MDS Logo
Longitude, a Financial Times Company logo

How to deliver sustainable access to innovative cancer care in emerging markets

Cutting-edge cancer treatments – particularly in the field of immuno-oncology (IO) – are delivering a lifeline to patients. But as new therapies become available, even the best-resourced healthcare systems need to take decisions about how to provide access. The challenge is particularly acute in developing economies.

Throughout this series, MSD explores the reality of delivering better cancer treatment in emerging markets. In many cases, private health insurers are already making an impact through the development of new funding models.

So what are the lessons from innovative insurance programmes around the world that are increasing access to IO therapies – and what barriers are still stopping countries from expanding uptake?

How to widen access to ground-breaking cancer treatments

Innovation in cancer care faces an awareness challenge

Taking innovative cancer treatments to emerging markets

The growing importance of private health insurance

Connect with us

sustainableax@msd.com

How to deliver sustainable access to innovative cancer care in emerging markets

Cutting-edge cancer treatments – particularly in the field of immuno-oncology (IO) – are delivering a lifeline to patients. But as new therapies become available, even the best-resourced healthcare systems need to take decisions about how to provide access. The challenge is particularly acute in developing economies.

Throughout this series, MSD explores the reality of delivering better cancer treatment in emerging markets. In many cases, private health insurers are already making an impact through the development of new funding models.

So what are the lessons from innovative insurance programmes around the world that are increasing access to IO therapies – and what barriers are still stopping countries from expanding uptake?

How to widen access to ground-breaking cancer treatments

Innovation in cancer care faces an awareness challenge

Taking innovative cancer treatments to emerging markets

The growing importance of private health insurance

Explore our case studies

Case study: South Africa

Increasing access to cancer care: A Targeted Therapy Rider benefit

Case study: Indonesia

Striking a balance between access, innovation and affordability in cancer care

Case study: Dubai, UAE

An innovative public-private partnership funds better cancer care

Connect with us

sustainableax@msd.com

Copyright © 2009-2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A. All rights reserved.